SG11202113167QA - Fused heterocyclic derivatives - Google Patents

Fused heterocyclic derivatives

Info

Publication number
SG11202113167QA
SG11202113167QA SG11202113167QA SG11202113167QA SG11202113167QA SG 11202113167Q A SG11202113167Q A SG 11202113167QA SG 11202113167Q A SG11202113167Q A SG 11202113167QA SG 11202113167Q A SG11202113167Q A SG 11202113167QA SG 11202113167Q A SG11202113167Q A SG 11202113167QA
Authority
SG
Singapore
Prior art keywords
compound
formula
membered monocyclic
hbv
mmol
Prior art date
Application number
SG11202113167QA
Other languages
English (en)
Inventor
Sandrine Céline Grosse
Lindsey Graham Deratt
Koen Vandyck
Pierre Jean-Marie Bernard Raboisson
Serge Maria Aloysius Pieters
Bart Rudolf Romanie Kesteleyn
Wim Gaston Verschueren
Jan Martin Berke
Morgan Charles R Lecomte
Lamenca Carolina Martinez
Tim Hugo Maria Jonckers
Gang Deng
Yimin Jiang
Yanping Xu
Zhangling Cheng
Lili Hu
Scott D Kuduk
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71741889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202113167Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of SG11202113167QA publication Critical patent/SG11202113167QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202113167QA 2019-05-28 2020-05-27 Fused heterocyclic derivatives SG11202113167QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962853533P 2019-05-28 2019-05-28
EP19176933 2019-05-28
CN2020085720 2020-04-20
PCT/US2020/034643 WO2020243135A1 (en) 2019-05-28 2020-05-27 Fused heterocyclic derivatives

Publications (1)

Publication Number Publication Date
SG11202113167QA true SG11202113167QA (en) 2021-12-30

Family

ID=71741889

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113167QA SG11202113167QA (en) 2019-05-28 2020-05-27 Fused heterocyclic derivatives

Country Status (19)

Country Link
EP (1) EP3976617B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022535734A (cg-RX-API-DMAC7.html)
KR (1) KR20220012913A (cg-RX-API-DMAC7.html)
CN (1) CN113906028A (cg-RX-API-DMAC7.html)
AU (1) AU2020285718A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022889A8 (cg-RX-API-DMAC7.html)
CA (1) CA3138168A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003155A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016433A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210666A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000230A (cg-RX-API-DMAC7.html)
IL (1) IL288322A (cg-RX-API-DMAC7.html)
JO (1) JOP20210313A1 (cg-RX-API-DMAC7.html)
MA (1) MA56043A (cg-RX-API-DMAC7.html)
MX (1) MX2021014575A (cg-RX-API-DMAC7.html)
PE (1) PE20220767A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552974A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202113167QA (cg-RX-API-DMAC7.html)
WO (1) WO2020243135A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022116999A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives and their use in the treatment of hbv infection
WO2022116998A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives as hbv inhibitors
TW202237617A (zh) * 2020-12-02 2022-10-01 愛爾蘭商健生科學愛爾蘭無限公司 稠合雜環衍生物
AR126049A1 (es) 2021-06-02 2023-09-06 Janssen Sciences Ireland Unlimited Co Derivados heterocíclicos condensados
CA3218641A1 (en) * 2021-06-02 2022-12-08 Chunliang Lu Fused heterocyclic derivatives
WO2024114709A1 (en) * 2022-12-01 2024-06-06 Janssen Sciences Ireland Unlimited Company A crystal form of a fused heterocycle derivative compound
WO2024140851A1 (zh) * 2022-12-28 2024-07-04 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2993174A1 (en) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
WO2016109689A2 (en) * 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
CA3029566A1 (en) * 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
TW201806956A (zh) * 2016-06-29 2018-03-01 諾維拉治療公司 二氮呯酮衍生物及治療b型肝炎感染之方法
US20220306647A1 (en) * 2019-04-30 2022-09-29 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitus b virus (hbv)

Also Published As

Publication number Publication date
EP3976617B1 (en) 2025-04-23
JOP20210313A1 (ar) 2021-11-25
CL2021003155A1 (es) 2022-07-22
MA56043A (fr) 2022-04-06
MX2021014575A (es) 2022-05-24
WO2020243135A1 (en) 2020-12-03
PH12021552974A1 (en) 2022-07-11
AU2020285718A1 (en) 2022-02-03
CR20210666A (es) 2022-03-11
PE20220767A1 (es) 2022-05-16
EP3976617A1 (en) 2022-04-06
CO2021016433A2 (es) 2021-12-10
BR112021022889A8 (pt) 2024-03-05
DOP2021000230A (es) 2022-05-31
KR20220012913A (ko) 2022-02-04
CN113906028A (zh) 2022-01-07
BR112021022889A2 (pt) 2022-01-04
CA3138168A1 (en) 2020-12-03
IL288322A (en) 2022-01-01
JP2022535734A (ja) 2022-08-10

Similar Documents

Publication Publication Date Title
EP3976617B1 (en) Fused heterocyclic derivatives
US20210252014A1 (en) Oxadiazepinone derivatives and methods of treating hepatitis b infections
US11504382B2 (en) Tricyclic inhibitors of Hepatitis B virus
CN111511747A (zh) 用于治疗与hbv感染相关的疾病的异噁唑化合物
EP4347036A1 (en) Fused heterocyclic derivatives
US20220348592A1 (en) Fused heterocyclic derivatives
JP2022534960A (ja) カプシド集合修飾因子としてのジアゼピノン誘導体
WO2020239864A1 (en) Fused heterocycle derivatives as capsid assembly modulators
EA047929B1 (ru) Сочлененные гетероциклические производные
JP2022535208A (ja) 抗ウイルス剤としての縮合ヘテロ環誘導体
HK40066700A (zh) 稠合杂环衍生物
US20240287070A1 (en) Fused heterocyclic derivatives
WO2026101971A2 (en) Egfr inhibitors for treating disease
WO2022116998A1 (en) Fused heterocyclic derivatives as hbv inhibitors
HK40033068A (en) Isoxazole compounds for the treatment of diseases associated with hbv infections